Condition
Functional Pancreatic Neuroendocrine Tumor
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT02420691Phase 2Completed
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
NCT02831179Phase 1WithdrawnPrimary
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Showing all 2 trials